oncocalyxone A

a 1,4-anthracenedione isolated from Auxemma oncocalyx (Boraginaceae) that has been shown to be cytotoxic to tumor cells in vitro

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Anthracenes: 12
        Anthrones: 12
        Anthraquinones: 788
        oncocalyxone A: 4
- Quinones: 434
  - Anthraquinones: 788
    - oncocalyxone A: 4
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Anthracenes: 12
    - Anthrones: 12
      - Anthraquinones: 788
        oncocalyxone A: 4

Experts

1.	Barros-Nepomuceno, Francisco Washington Araújo: 1 article (01/2021)
2.	Cavalcanti, Bruno Coêlho: 1 article (01/2021)
3.	Costa, Marcília Pinheiro da: 1 article (01/2021)
4.	Ferreira, Paulo Michel Pinheiro: 1 article (01/2021)
5.	Pessoa, Cláudia: 1 article (01/2021)
6.	Pessoa, Otília Deusdênia Loiola: 1 article (01/2021)
7.	Ramos de Sousa, Rayran Walter: 1 article (01/2021)
8.	Sbardelotto, Aline Borba: 1 article (01/2021)
9.	Soares, Bruno Marques: 1 article (01/2021)
10.	Barreto, Antônio C H: 1 article (09/2013)

Related Diseases

1.	Leukemia 01/01/2021 - "The aim of this study was to (1) examine the cytotoxic actions of oncocalyxone A on human normal and tumor cell lines and (2) determine mechanistic actions underlying effects upon leukemia cells using cellular and molecular techniques. " 01/01/2021 - "To understand cytotoxicity, assessments were performed with HL-60 leukemia cells (8, 16.5, or 33 µM) after 24 hr incubation using light and fluorescence microscopy, trypan blue, flow cytometry, Comet assay, western blot of caspases and poly-ADP-ribose polymerase (PARP), and effects on topoisomerase I and II. Oncocalyxone A exhibited cytotoxic action upon HL-60 cells and dividing leukocytes, but minimal hemolytic action on erythrocytes. "
2.	Neoplasms (Cancer) 09/05/2013 - "Magnetic nanosystem for cancer therapy using oncocalyxone a, an antitomour secondary metabolite isolated from a Brazilian plant." 09/01/2023 - "In addition to the antimicrobial effects against protozoa, fungi and bacteria and relaxation of smooth muscles, oncocalyxone A reduces mean blood pressure and glycemia in diabetic rats, decreases glomerular filtration parameters and tubular transport of electrolytes, and presents in vitro antimitotic and cytotoxic action upon different types of cancers, including resistant lung carcinoma lines. "
3.	Chronic Disease (Chronic Diseases) 09/01/2023 - "Moreover, slight systemic deleterious effects in mammals stimulate the use of oncocalyxone A and related compounds as lead constituents of safer drugs against chronic diseases."
4.	Chromosome Aberrations (Chromosome Abnormalities) 01/01/2003 - "The association between therapeutic and genotoxic properties of oncocalyxone A (Onco A), make cytotoxic tests (mitotic index and chromosomal aberrations) fundamental in the accompaniment of the effects of this active compound. "
5.	Carcinoma (Carcinomatosis) 09/01/2023 - "In addition to the antimicrobial effects against protozoa, fungi and bacteria and relaxation of smooth muscles, oncocalyxone A reduces mean blood pressure and glycemia in diabetic rats, decreases glomerular filtration parameters and tubular transport of electrolytes, and presents in vitro antimitotic and cytotoxic action upon different types of cancers, including resistant lung carcinoma lines. "

Related Drugs and Biologics

1.	Antimitotic Agents
2.	Caspases
3.	Trypan Blue
4.	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
5.	Electrolytes
6.	Type I DNA Topoisomerases (Topoisomerase I)

Related Therapies and Procedures

1.	Therapeutics